FundedStartupsDaily / HealthTech / Seawolf Therapeutics

Seawolf Therapeutics raises $100M

Seawolf Therapeutics announced a Series A round of $100M on 16 November 2026. The company operates in HealthTech and is based in United States. It was founded by Elizabeth Alcamo, President & CEO. Announced 2 days ago.

Raised
$100M
Stage
Series A
Industry
HealthTech
Country
United States

Founder

Elizabeth Alcamo
President & CEO, Seawolf Therapeutics
LinkedIn not availableseawolftx.com

Outreach angles

  • -Elizabeth Alcamo leads Seawolf as president and CEO as it emerges from stealth to develop redosable LNP-based DNA medicines.
  • -Alcamo says the Sanofi collaboration and investor syndicate position Seawolf to advance its lead metabolic disease programme.
  • -The $100M across seed and Series A came alongside a Sanofi licence deal worth up to $1.2 billion in milestones plus royalties.

Signals

Series ADeep TechHealthcareRegulated Industry

Round details

Company: Seawolf Therapeutics
Domain: seawolftx.com
Amount: $100M
Stage: Series A
Industry: HealthTech
Country: United States
Announced: 16 November 2026
Source: announcement

Other HealthTech raises

Recently funded in United States